文献速递临床免疫临床微生物

检测新分泌抗体可预测原发性艰难梭菌感染不复发

Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.
PubMed 文献 · J Clin Microbiol · 2022-03-16

本研究纳入46例住院原发性艰难梭菌感染(CDI)患者,在症状出现后第1、2、4周采集血清和MENSA样本,检测针对10种艰难梭菌抗原的抗体。9例(19.5%)在8周内复发;37例未复发者中23例(62%)MENSA对三种毒素抗原(TcdB-CROP、TcdBvir-CROP和/或CDTb)呈阳性,而复发者中无一人(0%)阳性。早期MENSA阴性者复发相对风险高19倍。

要点

  • 原发性CDI后8周内复发率可达30%,MENSA早期抗体检测可识别低复发风险患者。
  • 未复发患者中62%(23/37)MENSA对三种毒素抗原阳性,复发患者中0%(0/9)阳性。
  • MENSA阴性对三种毒素抗原者复发相对风险高19倍,阳性者 unlikely 复发。

核心结论

  • 早期MENSA检测针对三种艰难梭菌毒素抗原的抗体可预测原发性CDI患者不复发。
  • MENSA阴性者复发相对风险高19倍,阳性者不太可能复发。

研究设计与样本

  • 在Emory大学医院纳入46例住院原发性CDI患者。
  • 在症状出现后第1、2、4周采集血清和MENSA样本。
  • 检测针对10种艰难梭菌抗原的抗体。

主要发现

  • 46例中9例(19.5%)在8周内复发。
  • 37例未复发者中23例(62%;23/37)MENSA对TcdB-CROP、TcdBvir-CROP和/或CDTb阳性。
  • 复发者中0%(0/9)对这三种毒素抗原产生抗体。
  • MENSA阳性反应出现早(症状出现后12天内),包括6例从未血清阳转者。
  • 血清反应趋势类似但峰值较晚且识别患者较少(51%;19/37)。

关键数值与推荐

  • MENSA对三种毒素抗原(TcdB-CROP、TcdBvir-CROP和/或CDTb)任一阳性定义为阳性反应。
  • MENSA阴性对三种毒素抗原者复发相对风险高19倍。

临床怎么用

  • 早期MENSA检测可识别复发低风险患者,阳性者不太可能复发。
  • MENSA阴性可识别复发高风险患者,为靶向预防策略提供机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Within 8 weeks of primary Clostridioides difficile infection (CDI), as many as 30% of patients develop recurrent disease with the associated risks of multiple relapses, morbidity, and economic burden. There are no clear clinical correlates or validated biomarkers that can predict recurrence during primary infection. This study demonstrated the potential of a simple test for identifying hospitalized CDI patients at low risk for disease recurrence. Forty-six hospitalized CDI patients were enrolled at Emory University Hospitals. Samples of serum and a novel matrix from circulating plasmablasts called "medium-enriched for newly synthesized antibodies" (MENSA) were collected during weeks 1, 2, and 4. Antibodies specific for 10 C. difficile antigens were measured in each sample. Among the 46 C. difficile-infected patients, 9 (19.5%) experienced recurrence within 8 weeks of primary infection. Among the 37 nonrecurrent patients, 23 (62%; 23/37) had anti-C. difficile MENSA antibodies specific for any of the three toxin antigens: TcdB-CROP, TcdBvir-CROP, and/or CDTb. Positive MENSA responses occurred early (within the first 12 days post-symptom onset), including six patients who never seroconverted. A similar trend was observed in serum responses, but they peaked later and identified fewer patients (51%; 19/37). In contrast, none (0%; 0/9) of the patients who subsequently recurred after hospitalization produced antibodies specific for any of the three C. difficile toxin antigens. Thus, patients with a negative early MENSA response against all three C. difficile toxin antigens had a 19-fold greater relative risk of recurrence. MENSA and serum levels of immunoglobulin A (IgA) and/or IgG antibodies for three C. difficile toxins have prognostic potential. These immunoassays measure nascent immune responses that reduce the likelihood of recurrence thereby providing a biomarker of protection from recurrent CDI. Patients who are positive by this immunoassay are unlikely to suffer a recurrence. Early identification of patients at risk for recurrence by negative MENSA creates opportunities for targeted prophylactic strategies that can reduce the incidence, cost, and morbidity due to recurrent CDI.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Haddad NS, Nozick S, Kim G, et al. Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection. J Clin Microbiol. 2022. PMID: 35107301. doi:10.1128/jcm.02201-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。